Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UI43
UPID:
MRM2_HUMAN
Alternative names:
16S rRNA (uridine(1369)-2'-O)-methyltransferase; 16S rRNA [Um1369] 2'-O-methyltransferase; Protein ftsJ homolog 2
Alternative UPACC:
Q9UI43; Q24JR8
Background:
rRNA methyltransferase 2, mitochondrial, also known as 16S rRNA (uridine(1369)-2'-O)-methyltransferase, plays a crucial role in mitochondrial function by catalyzing the formation of 2'-O-methyluridine at position 1369 in the 16S mitochondrial large subunit ribosomal RNA. This modification is universally conserved and essential for the proper assembly and function of the mitochondrial ribosome.
Therapeutic significance:
The protein is implicated in Mitochondrial DNA depletion syndrome 17, a severe mitochondrial disorder. Understanding the role of rRNA methyltransferase 2, mitochondrial could open doors to potential therapeutic strategies for this and related mitochondrial diseases.